TPIV News TapImmune Announces the Appointment of

TPIV News TapImmune Announces the Appointment of Mark Reddish to the Board of Directors

2012-04-30 09:31 ET - News Release

SEATTLE, April 30, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of Mark Reddish to the Board of Directors. Mark is currently Vice President of Development at TapImmune and is responsible for developing the Company's product pipeline. He was formerly Vice President of Research & Development and Principal Investigator, Biodefense at ID Biomedical, Bothell, WA, prior to the acquisition of the company by Glaxo SmithKline. At Biomira Inc, Edmonton, Alberta (now renamed Oncothyreon, Seattle) he was responsible for preclinical development of their cancer vaccine program where he led the early research and clinical development of both Theratope and Stimuvax. Stimuvax is currently in late Stage 3 Clinical Trials partnered with Merk KGa/ Serono. Mark's corporate experience also extends to Baxter Healthcare and Bayer AG. He has a degree in Biology from Bates College and did graduate studies in Microbiology/Immunology at University of Massachusetts.

Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome the appointment of Mark to the Board. Mark is a leader in the development of Immunotherapies for cancer and infectious disease and brings to the Board a unique perspective and breadth of experience in this emerging field. More importantly he understands the challenges and strategies for innovative product design and development required for creation of a leading Immunotherapy organization."

Mark Reddish added, "I want to thank Glynn for the opportunity to work with him and the rest of our Board and Advisors to fully develop TapImmune's potential. Our core technology platform provides enormous opportunities for the development of new intellectual property and important products together with the establishment of multiple business partnerships."